Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembrolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.
Completed · Phase 1
Conditions studied: Advanced Solid Tumor, Head and Neck Squamous Cell Carcinoma
In brief
This study is being done to learn more about a new drug called Bapotulimab given in combination with Pembrolizumab. The purpose of this study is to learn if this new combination of drugs is safe for the participants, how it affects the body and to try to find the best dose of the new drug to give to participants and to obtain a preliminary assessment of the tumor response efficacy in the recurrent or metastatic Head and Neck Cancer.
Key facts
- Study ID
- NCT03666273
- Run by
- Bayer
- People needed
- 60
- Starts
- 2018-09-12
- Expected to finish
- 2024-05-15
- Last updated by the study team
- 2024-05-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Arizona Cancer Center — Tucson, Arizona, United States
- Yale University School of Medicine — New Haven, Connecticut, United States
- University of Chicago Hospitals — Chicago, Illinois, United States
- Henry Ford Health System — Detroit, Michigan, United States
- University Hospitals Cleveland Medical Center — Cleveland, Ohio, United States
- Ohio State University — Columbus, Ohio, United States
- University of Texas MD Anderson Cancer Center — Houston, Texas, United States
- South Texas Accelerated Research Therapeutics | START San Antonio — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.